Discover Great Companies Discover Great Clients
Popularity  28.8万   |   Followers  141   |   Likes  126   |   Feedback  160 Claim this company

Caring for Public Health, Creating a Better Life Together

No.42 Shenzhen Popularity Ranking No.4 Longhua District No.76 Guangdong No.1 Antibiotics No.1 Zai Sheng Yi Xue No.1 Pharmaceutical Technology No.1 Xin Zhi Sheng Chan Li No.1 Rehabilitation Management No.1 Yu Fang Bao Jian No.1 Yi Yao Jing Ji No.1 Pharmaceutical R&D No.1 Health Technology No.1 Yao Li Yan Jiu No.1 Innovative Drugs Products No.1 Yuan Yan Yao 企业技术中心 科技型中小企业 国家科技进步奖 院士工作站 驰名商标 国家高新技术企业 GMP认证
More

Company Overview

  • Nature: Listed Company Size: 10,000+ employees Founded: 27年
  • Industry: Pharmaceutical/Biotechnology 、 Lifestyle Services
  • Full name: China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.。

Development Stage

  • Stage: IPO上市, 主板, 深交所。
  • Ranking: Ranked #42 in Shenzhen by popularity Ranked #1 in Shenzhen Antibiotics Company by popularity Ranked #1 in Shenzhen Zai Sheng Yi Xue Company by popularity Ranked #1 in Shenzhen Pharmaceutical Technology Company by popularity Ranked #1 in Shenzhen Xin Zhi Sheng Chan Li Company by popularity
  • Honors: 2022中国广东企业500强 2023中国中成药企业100强 企业技术中心 科技型中小企业 According to algorithm
  • News: 2026-02-06:华润三九:2025年净利润34.22亿元,同比增长1.60%。
  • Salary: 69.2% of positions earn 6-15K, In 2026 vs last yeargrew by 27%.。Master's salary: ¥16.6K, Doctorate salary: ¥17.0K.
  • R&D: "Medical & Health/Beauty & Healthcare" demand: 4.9%, "Computer/Network/Technology": 3.7%, "Other (R&D and Technical)": 2.5%。
  • Recruiting: In 2026 vs 2025decreased by 15%. Demand for highly educated talent: Master's: 19, Doctorate: 13.
  • Requirement: Education: 大专 leads with 52%. Experience: 1-3年 leads with 40.6%.
  • Region: Distributed across 40 regions, 深圳: 22.3%, 北京: 4.9%, 广州: 3.8%, 重庆: 3.2%.

About the Company

[Summary] Caring for Public Health, Creating a Better Life Together

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (referred to as "CR Sanjiu") is a large state-controlled listed pharmaceutical company, primarily engaged in the research, development, production, and sales of pharmaceutical products, as well as related health services. Since its listing, the company has been awarded the "Golden Bull Top 100" and "Value Top 100" enterprises among China's main board listed companies multiple times. As of now, CR Sanjiu has been included in the Shenzhen Component Index, CSI 500, and FTSE Russell indices.

CR Sanjiu's predecessor was Shenzhen Southern Pharmaceutical Factory, established in 1985. In 1999, it was restructured into a joint-stock company initiated by 5 companies, including Sanjiu Enterprise Group and Shenzhen Sanjiu Pharmaceutical Co., Ltd. On March 9, 2000, it was listed on the Shenzhen Stock Exchange (stock code: 000999). In 2008, it officially became part of China Resources Group. In 2010, the company name was changed from "Sanjiu Medical & Pharmaceutical Co., Ltd." to "China Resources Sanjiu Medical & Pharmaceutical Co., Ltd."

CR Sanjiu's core business is positioned in the CHC health consumer products and prescription drug sectors, with a rich product line that is continuously expanding. CHC health consumer products mainly cover categories such as colds, gastrointestinal, skin, liver and gallbladder, pediatrics, orthopedics, gynecology, cardiovascular and cerebrovascular, among others, with core products holding a significant market share. Prescription drug products cover therapeutic areas including cardiovascular and cerebrovascular, anti-tumor, digestive system, orthopedics, pediatrics, anti-infection, etc., featuring products such as Xuesaitong Sanqi series, Shenfu Injection, MitoXantrone Hydrochloride Injection for tracing, Huachansu tablets and injections, Yixuesheng Capsules, Yuxuebi, Cefobiprole Medocaril Sodium for Injection, which enjoy a high reputation in hospital settings. The company's TCM formula granules and prepared herbal slices are dedicated to creating "original quality and taste" 999 TCM formula granules and "Sanjiu Bencao Wu" premium herbal slices.

The "999" brand enjoys high recognition among consumers and in the pharmaceutical industry. Based on the "999" main brand, a "1+N" brand matrix has been constructed spanning the entire life cycle and all health management scenarios. Over the years, CR Sanjiu has consistently ranked first in the comprehensive ranking of OTC enterprises published by the China Nonprescription Medicines Association, with 999 Ganmaoling Granules/Capsules continuously winning first place in the category of cold and cough (Chinese patent medicine). Additionally, CR Sanjiu has multiple products ranked among the top in various lists.

Against the backdrop of constant changes in the pharmaceutical industry, CR Sanjiu embraces opportunities for industry and market development, leading "high-quality development" through innovation, adhering to the dual-driven approach of "brand + innovation," focusing on the innovative R&D and intelligent manufacturing of high-quality pharmaceutical health products, optimizing business layout, strengthening brand and channel construction, increasing innovation investment, actively exploring innovative models for industry chain development, building a competitive advantage in the entire TCM industry chain, improving operational quality and efficiency, and achieving steady improvement in business performance and core capabilities. In 2024, the company achieved operating revenue of RMB 27.617 billion, a year-on-year increase of 11.63%; total profit of RMB 4.594 billion, an increase of 22.35%; net profit attributable to shareholders of the listed company of RMB 3.368 billion, an increase of 18.05%; and net profit attributable to shareholders of the listed company excluding non-recurring gains and losses of RMB 3.118 billion, an increase of 15.01%.

CR Sanjiu has always attached great importance to R&D and innovation. Scientific research projects centered on the company's products "Shenfu Injection," "Honghua Injection," "Shenmai Injection," "Xintailin," "999 Lixuwang brand Xuesaitong Sanqi Soft Capsules," and "Artemisinin series" have successively won the second prize of the National Science and Technology Progress Award. During the "14th Five-Year Plan" strategic period, the company adheres to an innovation-driven strategy, building a systematic R&D system, continuously increasing R&D investment, strengthening the construction of scientific and technological talent echelons, and enhancing innovation and development capabilities. The company has established six institutes and three laboratories, including the Health Drug Research Institute, TCM Research Institute, and Innovative Drug Research Institute, focusing on innovative fields for the research and development of generic drugs, innovative drugs, and classic TCM formulas; the TCM Resources Research Institute focuses on the research, protection, development, and utilization of TCM resources; the Advanced Delivery Research Institute focuses on forward-looking and breakthrough research and incubation of common generic drug delivery technologies; and the Process Technology Research Institute focuses on improving process technology levels and strengthening industry chain collaboration efficiency. The Deep Blue Laboratory, Fuxi Laboratory, and Shuidi Laboratory capture strategic opportunities in intelligent TCM manufacturing, aging, and consumption upgrade to explore innovation potential. In terms of TCM heritage and innovation, CR Sanjiu accelerates the cultivation of new quality productive forces, continuously deepens the full-process TCM development system, and consolidates TCM R&D capabilities.

CR Sanjiu continuously pays attention to high-quality resources at home and abroad, making strategic moves in mergers and acquisitions. Kunming Pharmaceutical Group and Tasly have successively become holding listed companies of CR Sanjiu. CR Sanjiu will empower and develop in synergy with Kunming Pharmaceutical Group and Tasly. Among them, CR Sanjiu takes CHC as its core business, striving to become a leading enterprise in the industry; Tasly takes prescription drugs as its core business, striving to become a top brand in innovative TCM drugs and medical channels; and Kunming Pharmaceutical Group takes Sanqi products and premium national drugs as its core business, aiming to become a leader in the silver economy health industry.

Looking to the future, guided by the mission of "Caring for Public Health, Creating a Better Life Together," CR Sanjiu benchmarks against leading enterprises, continuously improves its business layout, and strives towards the goal of becoming China's leading enterprise in the public pharmaceutical health industry, committed to becoming the number one brand in China's pharmaceutical health sector.

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

CR Sanjiu Financing History (1 rounds)

Manage
IPO上市
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Market: 主板
  • Deal: 深交所

CR Sanjiu How Fast Is Hiring Growing? (475 open positions)

Manage
?
Growth Rate
2026 vs 2025
  • 2025: Up 52%
  • 2024: Up 103%
  • 2023: Up 6%
  • 2022: Down 61%
CR Sanjiu Year-by-Year Hiring:
* Hiring was generally low during 2020-2022 due to the pandemic
CR Sanjiu Campus Recruitment & Advanced Degree Talent Demand
Graduates 12 Interns 15 Master's 19 Doctorate 13
Note: How fast is hiring at China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. growing? CR Sanjiu2026: 982 openings (down 15%), 2025: 1149 openings (up 52%), 2024: 756 openings (up 103%), 2023: 373 openings (up 6%), 2022: 351 openings (down 61%), 2021: 903 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

CR Sanjiu Master's Degree Job Demand Analysis

(More)
?
Growth Rate
2026 vs 2025
  • 2025: Up 49%
  • 2024: Down 15%
  • 2023: Up 141%
  • 2022: Down 53%
CR Sanjiu Master's Hiring by Year:
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is master's hiring at China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. growing? CR SanjiuMaster's recruitment over the years: 2025: 52 openings (up 49%), 2024: 35 openings (down 15%), 2023: 41 openings (up 141%), 2022: 17 openings (down 53%), 2021: 36 openings. CR Sanjiu master talent ranking in Shenzhen: #209, CR Sanjiu master salary mostly around 10-30K.

CR Sanjiu Doctoral Degree Job Demand Analysis

(More)
How fast is doctoral hiring at China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. growing? . CR Sanjiu doctorate talent ranking in Shenzhen: #49, CR Sanjiu doctorate salary mostly around 10-20K.

CR Sanjiu R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.? Based on an analysis of CR Sanjiu's job postings over the past year, "Medical & Health/Beauty & Healthcare" demand: 4.9%, "Computer/Network/Technology": 3.7%, "Other (R&D and Technical)": 2.5%, "Biology/Pharmaceutical/Chemical/Environmental Protection": 2.1%, "Scientific Research": 1.5%, "Electrical/Energy/Power": 0.8%. For reference only.

CR Sanjiu — What Are the Salaries Like? (840 records)

Manage
salary range: 4.5K - 50K, 69.2% of roles pay ¥6-15K
Note: salary statistics are based on 840 salary records from the past year and depend on the job sample. For reference only.
How is the salary at China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.?CR Sanjiu69.2% of positions earn 6-15K, Fresh graduate salary: ¥10.7K。销售类 average salary ¥12.5K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of CR Sanjiu

(More)
Are salaries high at China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.? We provide: Information, Regional Manager, Promotion Specialist, Sales, Regional Manager, Intern, Finance Specialist, Senior Specialist, Trainer, Analyst, Distribution Representative, Development Manager, Management Trainee, Management Specialist, 合规, Technical Engineer, Operations, Sales Administrator, Regional Manager, Auditor. Click to view detailed salary analysis by job.

CR Sanjiu — Fortune 500? (More)

Yes, ranked in 中国广东企业500强:

  • NO.147 2022中国广东企业500强 >

Yes, ranked in 中国中成药企业100强:

  • NO.6 2023中国中成药企业100强 >
  • NO.6 2022中国中成药企业100强 >
  • NO.6 2021中国中成药企业100强 >

Job Category

  • 销售类
    63.6% of total 63.6%
  • 市场/公关/媒介类
    15.7% of total 15.7%
  • 经营管理类
    10.6% of total 10.6%
  • 医疗卫生/美容保健类
    8.1% of total 8.1%

Education

  • 大专
    52% of total 52%
  • 本科
    37.2% of total 37.2%
  • 硕士
    4.2% of total 4.2%
  • 不限
    3.8% of total 3.8%

Experience

  • 1-3年
    40.6% of total 40.6%
  • 不限
    35.3% of total 35.3%
  • 3-5年
    15.8% of total 15.8%
  • 5-10年
    6.9% of total 6.9%
View Detailed Analysis

What does China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. require? Who is CR Sanjiu hiring? CR Sanjiu recruitment: 销售类占比最多占63.6%,其次是市场/公关/媒介类占15.7%. What education can get in at CR Sanjiu? 大专占比最多占52%,其次是本科占37.2%. High education required at CR Sanjiu? 硕士占4.2%,博士占1.8%. Work experience required at CR Sanjiu? 1-3年占比最多占40.6%,其次是不限占35.3%. Where are the job locations at CR Sanjiu? 深圳占比最多占22.3%,其次是北京占4.9%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 166,421.7858万(元)
Legal Representative: 吴文多
Date Established:
Credit Code: 914403007109245909
Registered Address: 深圳市龙华区观湖街道观澜高新园区观清路1号

Partners & Suppliers

海顺新材为其提供冷冲压成型铝等药用包装材料,为2023年度第一大客户。 Source
供应商 化学制药企业
华润三九指定云南骐铭为其在云南地区的经销商之一 Source
合作客户 上游制药企业
控股股东,昆药集团向其销售药品和提供劳务 Source
供应商 医药工业
合作开展中医药健康管理项目,共同开发慢病调理产品 Source
合作客户 医药企业合作
安徽亳药千草中药科技有限公司作为中药材供应商,向华润三九提供中药饮片等产品。 Source
供应商 下游制药企业

People who follow CR Sanjiu also follow

CR Sanjiu Competitors (Similar Companies)

“Research, development, and production of anti-tumor and surgical medic”
“Large-scale pharmaceutical distribution enterprise”
“Let the light of life science shine into every corner of the earth”
“A renowned enterprise in China's liver disease and anti-tumor fields”
“Nature as the source, reshaping you and me”
“Seek and strive, protect and heal all beings”
“Experts in global pharmaceutical and healthcare”
“Trustworthy overall solution provider for medical systems”
“Committed to providing scenario-based power battery and energy storage”
“An internationally leading modern pharmaceutical flagship enterprise”
体外诊断试剂 诊断试剂 试剂 抗体
“Professional services for the entire clinical trial process of drug pr”
“Top 10 of China Light Industry Plastic Industry”
“Professional manufacturer and service provider of cranes”
“International engineering general contracting, import and export trade”

Discover Great Companies, Discover Great Clients

深圳公司名录 深圳“Longhua District”公司名录 深圳“抗生素”公司名录 深圳“制药/药业”公司名录 深圳“抗肿瘤药”公司名录 深圳“医药工业”公司名录 深圳“药物研发”公司名录 附近的公司

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates